Gabapentin in chronic daily headache prophylaxis
In a placebo-controlled study by Spira et al., gabapentin was significantly superior to placebo for the primary efficacy variable for chronic daily headache prophylaxis: 9.1% difference in headache-free rates. Other measures were also significantly better with gabapentin, including headache-free days/months, severity, and quality of life.
see page 1753
Gabapentin in the treatment of chronic daily headache
Commentary by Stephen D. Silberstein, MD, FACP
Chronic daily headache (CDH) refers to headache disorders that occur 15 or more days a month. It is not a diagnosis, but a group of disorders that includes chronic tension-type headache, chronic migraine (CM), new daily persistent headache, and hemicrania continua. All are now included in the new International …
Letters: Rapid online correspondence
- Response to Silberstein Commentary
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
